111 related articles for article (PubMed ID: 10677637)
1. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.
Groothuis DR; Benalcazar H; Allen CV; Wise RM; Dills C; Dobrescu C; Rothholtz V; Levy RM
Brain Res; 2000 Feb; 856(1-2):281-90. PubMed ID: 10677637
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion.
Groothuis DR; Ward S; Itskovich AC; Dobrescu C; Allen CV; Dills C; Levy RM
J Neurosurg; 1999 Feb; 90(2):321-31. PubMed ID: 9950504
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion.
Slevin ML; Piall EM; Aherne GW; Johnston A; Lister TA
Cancer Chemother Pharmacol; 1983; 10(2):112-4. PubMed ID: 6572569
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery.
Vavra M; Ali MJ; Kang EW; Navalitloha Y; Ebert A; Allen CV; Groothuis DR
Neuro Oncol; 2004 Apr; 6(2):104-12. PubMed ID: 15134624
[TBL] [Abstract][Full Text] [Related]
5. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML).
Levy RM; Major E; Ali MJ; Cohen B; Groothius D
J Neurovirol; 2001 Aug; 7(4):382-5. PubMed ID: 11517421
[TBL] [Abstract][Full Text] [Related]
6. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
7. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma.
Burk M; Volmer M; Fartash K; Schneider W
Arzneimittelforschung; 1995 May; 45(5):616-9. PubMed ID: 7612064
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
[TBL] [Abstract][Full Text] [Related]
9. Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain.
Levy RM; Ward S; Schalgeter K; Groothuis D
J Neurovirol; 1997 May; 3 Suppl 1():S74-5. PubMed ID: 9179800
[No Abstract] [Full Text] [Related]
10. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice.
Toyoshima S; Fukuma M; Seto Y; Fujita H; Fukushima K; Tomioka H; Sakurai T; Sugimoto Y; Yagi T; Hoshino T; Sowa T
Gan; 1981 Feb; 72(1):19-29. PubMed ID: 7274645
[TBL] [Abstract][Full Text] [Related]
11. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
Lindner LH; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
Int J Hematol; 2008 Nov; 88(4):381-386. PubMed ID: 18836794
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.
Cundy KC; Bidgood AM; Lynch G; Shaw JP; Griffin L; Lee WA
Drug Metab Dispos; 1996 Jul; 24(7):745-52. PubMed ID: 8818571
[TBL] [Abstract][Full Text] [Related]
14. The disposition of new arabinosylcytosine derivative-- 5'-chloro-5'-deoxy-arabinosylcytosine--in rats.
Novotný L; Reichelová V; Janků I; Rauko P; Ujházy V
Gen Pharmacol; 1995 Sep; 26(5):1101-5. PubMed ID: 7557257
[TBL] [Abstract][Full Text] [Related]
15. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
Slevin ML; Piall EM; Aherne GW; Johnston A; Sweatman MC; Lister TA
Br J Clin Pharmacol; 1981 Oct; 12(4):507-10. PubMed ID: 6945865
[TBL] [Abstract][Full Text] [Related]
17. Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats.
Genoni S; Palus V; Eminaga S; Cherubini GB
Vet Comp Oncol; 2016 Sep; 14(3):331-6. PubMed ID: 25041580
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
[TBL] [Abstract][Full Text] [Related]
19. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
20. Intravascular streaming and variable delivery to brain following carotid artery infusions in the Sprague-Dawley rat.
Saris SC; Wright DC; Oldfield EH; Blasberg RG
J Cereb Blood Flow Metab; 1988 Feb; 8(1):116-20. PubMed ID: 3339101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
